A Clinical Trial of YH14642 in Patients With Chronic Periodontal Disease (YH14642)
Primary Purpose
Chronic Periodontitis
Status
Completed
Phase
Phase 2
Locations
Korea, Republic of
Study Type
Interventional
Intervention
YH14642 500mg Tab
YH14642 500mg Tab
YH14642 500mg Tab
INSADOL[Zea mays L. extract] 35mg Tab
DENTISTA[Doxycycline hyclate] 20mg Cap
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Chronic Periodontitis
Eligibility Criteria
Inclusion Criteria:
- Subjects must be 20 years of age or older
- Have at least 18 natural teeth
- Four or more clinical attachment level(CAL) ≥ 3mm
- Four or more periodontal pockets with a probing depth (PD) ≥ 4mm
- Have Bleeding on probing
- Provide informed consent and willingness to cooperate with the study protocol
Exclusion Criteria:
- Forbidden History of Panax Notoginseng and Rehmanniae Radix Preparata
- Hypersensitivity of Doxycycline
- Hypersensitivity of Zea mays L. extract
- Critical diseases such as HIV previous three years
- Patients with mental retardation and dementia
- Systemic diseases such as diabetes and hypertension
- Patients who take Anticoagulants or Antiplatelet Agents
- Patients who have malignant tumor
- Smoker
- Continually use for 2weeks of phenytoin, calcium channel blocker, cyclosporin, coumarin, nonsteroidal anti-inflammatory drugs and aspirin use in the previous one month
- Patients who need malignant tumor
- Patients who received periodontal treatment within the last 6 months
- Pregnant or lactating females
Sites / Locations
- Seoul National University Dental Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Arm Type
Experimental
Experimental
Experimental
Active Comparator
Active Comparator
Placebo Comparator
Arm Label
YH14642 A-I
YH14642 A-II
YH14642 A-III
Active Comparator B
Active Comparator C
Placebo
Arm Description
Outcomes
Primary Outcome Measures
Change in probing pocket depth (PD)
Secondary Outcome Measures
Change in Clinical attachment level (CAL)
Change in Bleeding on probing(BOP)
change in Gingival index(GI)
Change in Plaque index (PI)
Change in Gingival recession(GR)
[Exploratory Outcome Measure] Change in Alveolar bone height(ABH)
[Exploratory Outcome Measure] Change in Alveolar bone density(ABD)
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01499225
Brief Title
A Clinical Trial of YH14642 in Patients With Chronic Periodontal Disease
Acronym
YH14642
Official Title
A Double-blind, Randomized, Parallel, Placebo-active Controlled, Multi-center Phase II Clinical Trial to Investigate the Efficacy and Safety of YH14642 Following 12-week Oral Administration in Patients With Chronic Periodontal Disease
Study Type
Interventional
2. Study Status
Record Verification Date
July 2014
Overall Recruitment Status
Completed
Study Start Date
December 2011 (undefined)
Primary Completion Date
July 2013 (Actual)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Yuhan Corporation
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study is designed to evaluate the efficacy and the safety of YH14642 in Korea patients with chronic periodontitis, in order to investigate the recommended therapeutic dose.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Periodontitis
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
InvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
162 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
YH14642 A-I
Arm Type
Experimental
Arm Title
YH14642 A-II
Arm Type
Experimental
Arm Title
YH14642 A-III
Arm Type
Experimental
Arm Title
Active Comparator B
Arm Type
Active Comparator
Arm Title
Active Comparator C
Arm Type
Active Comparator
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
YH14642 500mg Tab
Intervention Description
YH14642 500mg per day(once a day)
Intervention Type
Drug
Intervention Name(s)
YH14642 500mg Tab
Intervention Description
YH14642 1000mg per day(twice a day)
Intervention Type
Drug
Intervention Name(s)
YH14642 500mg Tab
Intervention Description
YH14642 2000mg per day(three times a day)
Intervention Type
Drug
Intervention Name(s)
INSADOL[Zea mays L. extract] 35mg Tab
Intervention Description
[Initiation dose : 4weeks after administraion] INSADOL[Zea mays L. extract] 210mg TAB per day
[Maintain dose : Between 4weeks and 8weeks after administraion] INSADOL[Zea mays L. extract] 105mg TAB per day
[Maintain dose : Between 8weeks and 12weeks after administraion] INSADOL[Zea mays L. extract] 105mg TAB per day
Intervention Type
Drug
Intervention Name(s)
DENTISTA[Doxycycline hyclate] 20mg Cap
Intervention Description
DENTISTA[Doxycycline hyclate] Cap 40mg per day
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo
Primary Outcome Measure Information:
Title
Change in probing pocket depth (PD)
Time Frame
baseline, 4weeks, 8weeks and 12weeks
Secondary Outcome Measure Information:
Title
Change in Clinical attachment level (CAL)
Time Frame
baseline, 4weeks, 8weeks and 12weeks
Title
Change in Bleeding on probing(BOP)
Time Frame
baseline, 4weeks, 8weeks and 12weeks
Title
change in Gingival index(GI)
Time Frame
baseline, 4weeks, 8weeks and 12weeks
Title
Change in Plaque index (PI)
Time Frame
baseline, 4weeks, 8weeks and 12weeks
Title
Change in Gingival recession(GR)
Time Frame
baseline, 4weeks, 8weeks and 12weeks
Title
[Exploratory Outcome Measure] Change in Alveolar bone height(ABH)
Time Frame
baseline and 12weeks
Title
[Exploratory Outcome Measure] Change in Alveolar bone density(ABD)
Time Frame
baseline and 12weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Subjects must be 20 years of age or older
Have at least 18 natural teeth
Four or more clinical attachment level(CAL) ≥ 3mm
Four or more periodontal pockets with a probing depth (PD) ≥ 4mm
Have Bleeding on probing
Provide informed consent and willingness to cooperate with the study protocol
Exclusion Criteria:
Forbidden History of Panax Notoginseng and Rehmanniae Radix Preparata
Hypersensitivity of Doxycycline
Hypersensitivity of Zea mays L. extract
Critical diseases such as HIV previous three years
Patients with mental retardation and dementia
Systemic diseases such as diabetes and hypertension
Patients who take Anticoagulants or Antiplatelet Agents
Patients who have malignant tumor
Smoker
Continually use for 2weeks of phenytoin, calcium channel blocker, cyclosporin, coumarin, nonsteroidal anti-inflammatory drugs and aspirin use in the previous one month
Patients who need malignant tumor
Patients who received periodontal treatment within the last 6 months
Pregnant or lactating females
Facility Information:
Facility Name
Seoul National University Dental Hospital
City
Seoul
Country
Korea, Republic of
12. IPD Sharing Statement
Citations:
PubMed Identifier
33197289
Citation
Khattri S, Kumbargere Nagraj S, Arora A, Eachempati P, Kusum CK, Bhat KG, Johnson TM, Lodi G. Adjunctive systemic antimicrobials for the non-surgical treatment of periodontitis. Cochrane Database Syst Rev. 2020 Nov 16;11(11):CD012568. doi: 10.1002/14651858.CD012568.pub2.
Results Reference
derived
Learn more about this trial
A Clinical Trial of YH14642 in Patients With Chronic Periodontal Disease
We'll reach out to this number within 24 hrs